Literature DB >> 15976295

Immunology. Close to the edge: neutralizing the HIV-1 envelope.

Gary J Nabel1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15976295     DOI: 10.1126/science.1114854

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  15 in total

1.  Stoichiometry of murine leukemia virus envelope protein-mediated fusion and its neutralization.

Authors:  Wu Ou; Jonathan Silver
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

Review 2.  Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Authors:  S Phogat; R T Wyatt; G B Karlsson Hedestam
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

Review 3.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

4.  Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).

Authors:  Beda Joos; Alexandra Trkola; Herbert Kuster; Leonardo Aceto; Marek Fischer; Gabriela Stiegler; Christine Armbruster; Brigitta Vcelar; Hermann Katinger; Huldrych F Günthard
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane.

Authors:  Marinieve Montero; Naveed Gulzar; Kristina-Ana Klaric; Jason E Donald; Christa Lepik; Sampson Wu; Sue Tsai; Jean-Philippe Julien; Ann J Hessell; Shixia Wang; Shan Lu; Dennis R Burton; Emil F Pai; William F Degrado; Jamie K Scott
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

6.  Reactivity profiles of broadly neutralizing anti-HIV-1 antibodies are distinct from those of pathogenic autoantibodies.

Authors:  Harvir Singh; Kevin A Henry; Sampson S T Wu; Andrzej Chruscinski; Paul J Utz; Jamie K Scott
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

7.  Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites.

Authors:  Bruce K Brown; Nicos Karasavvas; Zoltan Beck; Gary R Matyas; Deborah L Birx; Victoria R Polonis; Carl R Alving
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

8.  Contribution of V(H) replacement products to the generation of anti-HIV antibodies.

Authors:  Hongyan Liao; Jun-tao Guo; Miles D Lange; Run Fan; Michael Zemlin; Kaihong Su; Yongjun Guan; Zhixin Zhang
Journal:  Clin Immunol       Date:  2012-11-15       Impact factor: 3.969

9.  Elimination of helminth infection restores HIV-1C vaccine-specific T cell responses independent of helminth-induced IL-10.

Authors:  Akram A Da'dara; Donald A Harn
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

10.  Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.

Authors:  Wu Ou; Ning Lu; Sloane S Yu; Jonathan Silver
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.